2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hole-in-one: simple non-surgical technique for the management of anterior chamber migrated Ozurdex ® implant

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: The migration of a dexamethasone implant to the anterior chamber is a vision-threatening complication which can happen in non-compartmentalized eyes treated with this device. Previous literature suggests that the solution to this complication is almost always surgical and in most cases cannot be delayed.

          Case description: We present the case of a 78-year-old woman with a scleral-fixated IOL and macular edema treated with Ozurdex ®. She came to us complaining of blurred vision and was subsequently diagnosed with an anterior-chamber migration of her dexamethasone implant. Postural manoeuvres were performed until the dexamethasone implant returned to the vitreous cavity through the pupil. Pilocarpine drops were prescribed with a positive outcome and no further migrations were described.

          Discussion: This case shows a practical and efficient way of managing a potentially vision-threatening complication without placing the patient onto an operating table. It is interesting to see how it is possible to relocate a dexamethasone implant despite the presence of a scleral-fixated IOL.

          Conclusion: Postural manoeuvres are an interesting option in patients with a dexamethasone implant migrated to the anterior chamber. This approach can have very positive outcomes, in addition to avoiding surgery, with all the risks and complications involved.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.

          To evaluate the safety and efficacy of 2 doses of dexamethasone intravitreal implant (DEX implant) for treatment of noninfectious intermediate or posterior uveitis. In this 26-week trial, eyes with noninfectious intermediate or posterior uveitis were randomized to a single treatment with a 0.7-mg DEX implant (n = 77), 0.35-mg DEX implant (n = 76), or sham procedure (n = 76). The main outcome measure was the proportion of eyes with a vitreous haze score of 0 at week 8. The proportion of eyes with a vitreous haze score of 0 at week 8 was 47% with the 0.7-mg DEX implant, 36% with the 0.35-mg DEX implant, and 12% with the sham (P .05 at any visit). The incidence of cataract reported in the phakic eyes was 9 of 62 (15%) with the 0.7-mg DEX implant, 6 of 51 (12%) with the 0.35-mg DEX implant, and 4 of 55 (7%) with the sham (P > .05). In patients with noninfectious intermediate or posterior uveitis, a single DEX implant significantly improved intraocular inflammation and visual acuity persisting for 6 months. Application to Clinical Practice Dexamethasone intravitreal implant may be used safely and effectively for treatment of intermediate and posterior uveitis. Trial Registration clinicaltrials.gov Identifier: NCT00333814.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies.

            To describe the risk factors, clinical course, and complications of migration of a dexamethasone (DEX) intravitreal implant (OZURDEX; Allergan, Inc., Irvine, CA) into the anterior chamber and subsequent management strategies.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®).

                Bookmark

                Author and article information

                Journal
                GMS Ophthalmol Cases
                GMS Ophthalmol Cases
                GMS Ophthalmol Cases
                GMS Ophthalmology Cases
                German Medical Science GMS Publishing House
                2193-1496
                27 February 2020
                2020
                : 10
                : Doc05
                Affiliations
                [1 ]Department of Ophthalmology, Basurto University Hospital, Bilbao, Spain
                [2 ]Madrid, Spain
                [3 ]Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Lejona, Vizcaya, Spain
                Author notes
                *To whom correspondence should be addressed: Pablo Rivera-Pérez de Rada, Department of Ophthalmology, Avenida Montevideo 18, Basurto University Hospital, Bilbao, Spain, E-mail: riveraperezderada@ 123456gmail.com
                Article
                oc000132 Doc05 urn:nbn:de:0183-oc0001322
                10.3205/oc000132
                7113619
                32269903
                e011dee6-1f9e-4d77-8e21-d25244594847
                Copyright © 2020 Rivera-Pérez de Rada et al.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

                History
                Categories
                Article

                dexamethasone,macular edema,pupil,anterior chamber,piilocarpine,intravitreal injections,corneal endothelium,posterior eye segment,hospital emergency service

                Comments

                Comment on this article